Monk, B., Tewari, K., Dubot, C., Caceres, M., Hasegawa, K., Shapira-Frommer, R., . . . Lorusso, D. (2023). Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): A randomised, double-blind, placebo-controlled, phase 3 trial.
Citación estilo ChicagoMonk, BJ, et al. Health-related Quality of Life With Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. 2023.
Cita MLAMonk, BJ, et al. Health-related Quality of Life With Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. 2023.
